Florida International University (FIU) is seeking a business partner to develop and commercialize Compositions and Methods for Targeted Delivery to the Gut Associated Lymphoid Tissue (GALT). These compositions can survive stomach digestion, allowing sustained release of therapeutic agents in the intestine, and inhibition of human immunodeficiency virus 1 (HIV-1) infection in the GALT.
HIV-1 still remains one of the leading life-threatening diseases in the world. The introduction of Highly Active Antiretroviral Therapy (HAART) has significantly reduced HIV-infection-related morbidity and mortality. However, most antiretroviral drugs have a short half-life and need to be in circulation constantly to control the virus replication. As a result, it is believed that missing a medication dose even once can provide an opportunity for viruses to replicate such that a medication resistant HIV strain may develop. Being the largest lymphoid organ, the gastrointestinal tract plays a key role in not only early HIV infection in establishing viral reservoirs in gut-associated lymphoid tissue (GALT) but also disease pathology. Many different treatment options have been proposed to eradicate the virus from GALT; however, due to the complex physiology involved, it is difficult to design drugs that are targeted toward GALT.
FIU inventors have developed nanodrugs comprising an active agent, a poloxamer, and an antibody to glycoprotein-2 (GP2) or antibody fragment to GP2 that targets microfold cells (M-cells) and facilitates the uptake of the nanodrug by M-cells. M-cells are specialized epithelial cells that are predominantly present in the GALT. Once attached to the M-cells, the nanodrugs are transferred from intestine to GALT via transcytosis mechanisms.
- Targeted nanodrug delivery to the GALT
- Treatment of HIV-1 infection
- Survive stomach digestion
- Reduce therapeutic dosage and associated side effects
- Directly act on the HIV-1 in GALT